EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field

Sheila F Lumley, Jolynne Mokaya, Tongai G Maponga, Anna Kramvis, Geoffrey Dusheiko, William Irving, Marion Delphin, Khadija Said Mohammed, Louise O Downs, Elizabeth Waddilove, Motswedi Anderson, Collins Iwuji und 32 weitere

The Lancet Microbe · 2025-08 · 6 (8) · 101076

DOI: 10.1016/j.lanmic.2025.101076 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2025-08. Verfasst von Sheila F Lumley und 43 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Medicine, University of Oxford, Oxford, UK; Department of Infectious Diseases and Microbiology, Oxford University Hospitals, O…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B virus, Drug Resistance, Viral, Hepatitis B, Chronic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Wellcome Trust, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B virusDrug Resistance, ViralHepatitis B, ChronicHepatitis BHumansWorld Health OrganizationTenofovirGuanineGlobal Health

Substanzen

Antiviral AgentsTenofovirentecavirGuanine

Autor:innen und Institutionen

  • Nuffield Department of Medicine, University of Oxford, Oxford, UK; Department of Infectious Diseases and Microbiology, Oxford University Hospitals, Oxford, UK.
  • Parasites and Microbes, Wellcome Sanger Institute, Cambridge, UK.
  • Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; National Health Laboratory Service, Tygerberg Business Unit, Cape Town, South Africa.
  • Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.
  • University of the Witwatersrand, Johannesburg, South Africa; Institute of Liver Studies, King's College Hospital, London, UK.
  • NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.

Förderung

  • World Health Organization
  • Wellcome Trust
  • National Institute of Allergy and Infectious Diseases
  • The Francis Crick Institute
  • National Institutes of Health
  • Ministerie van Volksgezondheid, Welzijn en Sport
  • Secretaría Nacional de Ciencia, Tecnología e Innovación
  • National Institute for Health and Care Research

Zitieren

APA

Lumley, S. F., Mokaya, J., Maponga, T. G., Kramvis, A., Dusheiko, G., Irving, W., Delphin, M., Said Mohammed, K., Downs, L. O., Waddilove, E., Anderson, M., Iwuji, C., Msomi, N., Ocama, P., Hamid, S., Adda, D., Halford, R., Kabagambe, K., Benschop, K. S. M., …, & Matthews, P. C. (2025). Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field. The Lancet Microbe, 6(8), 101076. https://doi.org/10.1016/j.lanmic.2025.101076

Vancouver

Lumley SF, Mokaya J, Maponga TG, Kramvis A, Dusheiko G, Irving W, et al. Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field. The Lancet Microbe. 2025;6(8):101076. doi:10.1016/j.lanmic.2025.101076

BibTeX
@article{Lumley2025,
  author = {Lumley, Sheila F and Mokaya, Jolynne and Maponga, Tongai G and Kramvis, Anna and Dusheiko, Geoffrey and Irving, William and Delphin, Marion and Said Mohammed, Khadija and Downs, Louise O and Waddilove, Elizabeth and Anderson, Motswedi and Iwuji, Collins and Msomi, Nokukhanya and Ocama, Ponsiano and Hamid, Saeed and Adda, Danjuma and Halford, Rachel and Kabagambe, Kenneth and Benschop, Kimberley S M and Inzaule, Seth and Chan, Polin and Paul, Margaret Alia Samson and Izumi, Kiyohiko and Nisa, Tiara and De Dieu Iragena, Jean and Girón-Callejas, Amalia and Kpossou, Aboudou Raïmi and Jamiyu, Ganiyu and Emmanuel, Omolara and Balkissa, Mahamadou and Keita, Mamadou and Prabdial-Sing, Nishi and Martinez, Alexander and Magongo, Eleanor Namusoke and Shao, Yiming and Sued, Omar and Sereno, Leandro Soares and Shafer, Robert W and Lesi, Olufunmilayo and Faini, Diana and Easterbrook, Philippa and Duncombe, Chris and Jordan, Michael R and Matthews, Philippa C},
  title = {Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field},
  journal = {The Lancet Microbe},
  year = {2025},
  volume = {6},
  number = {8},
  pages = {101076},
  doi = {10.1016/j.lanmic.2025.101076}
}
Kostenlos starten →